FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394845> ?p ?o ?g. }

• W4308394845 abstract "<h3>Background</h3> The benefit from immune checkpoint inhibitors (IO) is tempered by immune-related adverse events (IrAEs), which involve diverse organs, have varying biology, onset time, and severity. Several reports have found correlation between IrAE and better outcome, suggesting they may even serve as a surrogate of response, but studies are conflicting on the magnitude and significance of this correlation. Estimating the true incidence of IrAEs is particularly important in the early phase 1/2 trial setting, in order to avoid the risk of both over- and under-estimation. A key issue is the lack of IrAE diagnostic criteria, necessary to discriminate pure IrAEs from other treatment-related adverse events not sustained by an autoimmune process. <h3>Methods</h3> Of 421 patients enrolled in phase 1-2 trials, we identified patients treated with immune-oncology (IO) drugs and analysed clinical characteristics, temporal dynamics and correlation with survival of treatment-related events, identifying “High Confidence IrAEs” (HC IrAE) by careful reconsideration of available clinical parameters. We developed an IrAE Scoring System (ISS) based on 5 parameters, each ranging 0-2: available biopsy or specific test, response to immunosuppression, temporal correlation, evidence ruling out alternative cause, known IO relationship. Correlation with Overall Survival was explored by multivariate Cox proportional hazard analysis including multiple covariates (BMI, Age, tumor type, NLR, prior IO, prior Autoimmune disease, PS, baseline disease burden). To mitigate immortal time-bias, analyses were conducted i) at 2-month landmark and ii) modeling IrAEs as time-dependent covariate. <h3>Results</h3> 204 patients were treated with IO agents (41 with anti-PD(L)1 alone, 33 with non-PD(L)1 agents, 130 with combinations). 53 (25.9%) patients developed ≥ 1 treatment-related adverse event (85 total events). ISS score ranged from 0 to 8; by ROC analysis, a cutoff ≥ 5 achieved 100% specificity and 90% sensitivity to identify bona fide IrAEs. Based on this, we identified 3 groups of patients: 151 never experiencing an IrAE (“no-IrAE”), 33 low-confidence IrAE with ISS score 0-4 (“LC-IrAE”) and 20 high-confidence IrAE with ISS 5-8 (“HC-IrAE”). Compared to no-IrAE, patients experiencing HC-IrAEs had significantly lower Hazard ratio (HR) both in landmark analysis (HR=?0.242, 95% CI 0.117-0.500, p=0.0001) and IrAE as time-dependent covariate analysis ?(HR=0.244, 95% CI 0.116-0.511, p=0.0001); HR for patients experiencing LC IrAE, instead, was not statistically significant (figure 1). <h3>Conclusions</h3> ISS criteria provide a simple system to identify high confidence IrAEs, leading to more reliable estimates of IrAE incidence with significant impact on survival. <h3>Ethics Approval</h3> The study was approved by the local ethics committee with number UID 3560" @default.
• W4308394845 created "2022-11-11" @default.
• W4308394845 creator A5000459628 @default.
• W4308394845 creator A5001542206 @default.
• W4308394845 creator A5003897511 @default.
• W4308394845 creator A5004016231 @default.
• W4308394845 creator A5004442232 @default.
• W4308394845 creator A5006175430 @default.
• W4308394845 creator A5016428135 @default.
• W4308394845 creator A5016762975 @default.
• W4308394845 creator A5021812623 @default.
• W4308394845 creator A5022239860 @default.
• W4308394845 creator A5026861056 @default.
• W4308394845 creator A5040310185 @default.
• W4308394845 creator A5042037475 @default.
• W4308394845 creator A5043296077 @default.
• W4308394845 creator A5044558840 @default.
• W4308394845 creator A5053069568 @default.
• W4308394845 creator A5056831927 @default.
• W4308394845 creator A5082304162 @default.
• W4308394845 creator A5089140607 @default.
• W4308394845 creator A5090243964 @default.
• W4308394845 date "2022-11-01" @default.
• W4308394845 modified "2023-09-30" @default.
• W4308394845 title "1264 A set of easy and stringent criteria to identify Immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1–2 trial population" @default.
• W4308394845 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1264" @default.
• W4308394845 hasPublicationYear "2022" @default.
• W4308394845 type Work @default.
• W4308394845 citedByCount "0" @default.
• W4308394845 crossrefType "proceedings-article" @default.
• W4308394845 hasAuthorship W4308394845A5000459628 @default.
• W4308394845 hasAuthorship W4308394845A5001542206 @default.
• W4308394845 hasAuthorship W4308394845A5003897511 @default.
• W4308394845 hasAuthorship W4308394845A5004016231 @default.
• W4308394845 hasAuthorship W4308394845A5004442232 @default.
• W4308394845 hasAuthorship W4308394845A5006175430 @default.
• W4308394845 hasAuthorship W4308394845A5016428135 @default.
• W4308394845 hasAuthorship W4308394845A5016762975 @default.
• W4308394845 hasAuthorship W4308394845A5021812623 @default.
• W4308394845 hasAuthorship W4308394845A5022239860 @default.
• W4308394845 hasAuthorship W4308394845A5026861056 @default.
• W4308394845 hasAuthorship W4308394845A5040310185 @default.
• W4308394845 hasAuthorship W4308394845A5042037475 @default.
• W4308394845 hasAuthorship W4308394845A5043296077 @default.
• W4308394845 hasAuthorship W4308394845A5044558840 @default.
• W4308394845 hasAuthorship W4308394845A5053069568 @default.
• W4308394845 hasAuthorship W4308394845A5056831927 @default.
• W4308394845 hasAuthorship W4308394845A5082304162 @default.
• W4308394845 hasAuthorship W4308394845A5089140607 @default.
• W4308394845 hasAuthorship W4308394845A5090243964 @default.
• W4308394845 hasBestOaLocation W43083948451 @default.
• W4308394845 hasConcept C117220453 @default.
• W4308394845 hasConcept C119043178 @default.
• W4308394845 hasConcept C119857082 @default.
• W4308394845 hasConcept C126322002 @default.
• W4308394845 hasConcept C143998085 @default.
• W4308394845 hasConcept C197934379 @default.
• W4308394845 hasConcept C207103383 @default.
• W4308394845 hasConcept C2524010 @default.
• W4308394845 hasConcept C2780252810 @default.
• W4308394845 hasConcept C33923547 @default.
• W4308394845 hasConcept C41008148 @default.
• W4308394845 hasConcept C44249647 @default.
• W4308394845 hasConcept C50382708 @default.
• W4308394845 hasConcept C535046627 @default.
• W4308394845 hasConcept C71924100 @default.
• W4308394845 hasConceptScore W4308394845C117220453 @default.
• W4308394845 hasConceptScore W4308394845C119043178 @default.
• W4308394845 hasConceptScore W4308394845C119857082 @default.
• W4308394845 hasConceptScore W4308394845C126322002 @default.
• W4308394845 hasConceptScore W4308394845C143998085 @default.
• W4308394845 hasConceptScore W4308394845C197934379 @default.
• W4308394845 hasConceptScore W4308394845C207103383 @default.
• W4308394845 hasConceptScore W4308394845C2524010 @default.
• W4308394845 hasConceptScore W4308394845C2780252810 @default.
• W4308394845 hasConceptScore W4308394845C33923547 @default.
• W4308394845 hasConceptScore W4308394845C41008148 @default.
• W4308394845 hasConceptScore W4308394845C44249647 @default.
• W4308394845 hasConceptScore W4308394845C50382708 @default.
• W4308394845 hasConceptScore W4308394845C535046627 @default.
• W4308394845 hasConceptScore W4308394845C71924100 @default.
• W4308394845 hasLocation W43083948451 @default.
• W4308394845 hasOpenAccess W4308394845 @default.
• W4308394845 hasPrimaryLocation W43083948451 @default.
• W4308394845 hasRelatedWork W2072196024 @default.
• W4308394845 hasRelatedWork W2104184505 @default.
• W4308394845 hasRelatedWork W2119154902 @default.
• W4308394845 hasRelatedWork W2133235702 @default.
• W4308394845 hasRelatedWork W2136543019 @default.
• W4308394845 hasRelatedWork W2203903734 @default.
• W4308394845 hasRelatedWork W2343768426 @default.
• W4308394845 hasRelatedWork W2759177551 @default.
• W4308394845 hasRelatedWork W2917746345 @default.
• W4308394845 hasRelatedWork W4213083369 @default.
• W4308394845 isParatext "false" @default.
• W4308394845 isRetracted "false" @default.
• W4308394845 workType "article" @default.